



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 30 Jan 2023 (#05)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Important Notices

**Gearing Up for Transition to FORMS-H Application Forms:** As [announced](#) over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates **on or after January 25, 2023**. The [How to Apply – Application Guide](#) was updated on October 25 with FORMS-H application form instructions to prepare for the transition. Also see **Guide Notice [NOT-OD-23-012](#)**. All form changes are listed in [High-level Grant Application Form Change Summary: FORMS-H](#).

- **A key change in FORMS-H is support for the implementation of the 2023 [NIH Data Management and Sharing Policy](#)**. NIH expects applicants to submit a plan for how they will manage and share their data and allows applicants to include certain costs associated with data management and sharing in their budget.
  - [Writing a Data Management & Sharing Plan](#). Learn what NIH expects Data Management & Sharing plans to address.
  - [Budgeting for Data Management & Sharing](#). Find out what data sharing related costs may be requested in an application for funding.
  - [Sample DMS Plans to get you started](#)

**[NOT-OD-23-053](#) Reminder: NIH Policy for Data Management and Sharing effective on January 25, 2023.** The new DMS Policy promotes transparency and accountability in research by setting a minimum set of expectations for data management and sharing. This means that other NIH policies or NIH Institutes, Centers, Offices, or programs may build upon these expectations, for instance, by specifying scientific data to share, relevant standards, repository timelines, and/or shorter data sharing timelines for meeting programmatic needs, the DMS Policy sets a consistent baseline across NIH. In preparing for DMS Policy implementation, NIH has developed a number of helpful resources that we encourage investigators and institutions to review:

- [DMS Policy Overview](#)
- [DMS Policy FAQs](#)
- [Learning Resources](#) including 2-part webinar series on DMS Policy
- [Statements and Guide Notices](#)

**[NOT-DK-23-006](#) Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in Parkinson's Disease (U01 Clinical Trial Not Allowed).** This notice is to inform the research community that National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) intends to promote a new

initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to participate in the Gut-Brain Communication in Parkinson's Disease (PD) Consortium (GBPDC). The goals of this initiative are: 1) to establish a network of individual research projects and a Coordinating and Data Management Center (CDMC) focused on clinical research; 2) recruitment of sufficient patients and use of standardized protocols to collect data and biospecimens relevant to both neurology and gastroenterology research; 3) share data, biomaterials, models, reagents, resources and methods among projects in the GBPDC; and 4) make these publicly available through the CDMC. The objective of this consortium is to accelerate research on the role of gastrointestinal (GI) symptoms and changes in gut-brain communication in the initiation and pathogenesis of Parkinson's disease in order to facilitate development and validation of innovative early-phase GI-based diagnostic tools and biomarkers for PD. The research centers of the GBPDC will serve as sites for enrollment of PD patients and healthy age-matched controls for longitudinal studies involving the clinical assessment of relevant neurologic and GI function as well as laboratory-based studies on biological samples obtained from these patients. **First Estimated Application Due Date: October 10, 2023. Related Announcements: [NOT-DK-23-007](#)** - Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in Parkinson's Disease (U24 Clinical Trial Not Allowed).

**[NOT-AI-23-025](#) 2023 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2023-1.** If you can carry out research that supports program objectives of National Institute of Allergy and Infectious Diseases' (NIAID) [Division of Microbiology and Infectious Diseases](#) (DMID), consider submitting a proposal through the [2023 NIAID Omnibus Broad Agency Announcement](#) (BAA) contract solicitation. the 2023 BAA covers four distinct research areas. You may respond to one, any combination of, or all the research areas. For each research area, be sure to present separate, detailed technical and business proposals designed to meet the technical objectives described.

## Notices of Special Interest (NOSI)

**[NOT-CA-23-038](#) Administrative Supplements for NCI Global Oncology Mentored Research.** The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to support mentored cancer research career development of early-stage low- and middle-income country (LMIC) investigators (ESLIs). The overarching goal of this supplement opportunity is to strengthen the capacity of LMIC investigators to conduct high-quality research in their LMIC home institutions to generate context-appropriate evidence to address specific cancer control priorities in LMICs. Eligible activity codes for applications are limited to the following: R01, R35, R37, P01, P20, P50, U01, U19, U54, UH2, UH3, UG1, UG3 or UM1. No other grant or cooperative agreement mechanisms are eligible for this program. *Applications can be submitted on a rolling basis between April 22, 2023 - May 22, 2023, at 5:00 PM local time of applicant organization for FY 2023 funding. The NOSI will expire May 23, 2023.* The budget should not exceed \$125,000 in total costs. The application budget is limited to 1 year only. The project and budget periods must be within the currently approved project period for the existing parent award.

**[NOT-DA-24-001](#) Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine.** Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and pharmacokinetics has far-reaching implications. Substances of abuse (opioid, stimulants, nicotine, anxiolytics, alcohol, etc.) and its treatments (methadone, buprenorphine, extended naltrexone, etc.) may interact with ART, altering its bioavailability, its safety, and its efficacy. It is known that nevirapine and efavirenz increase methadone clearance. New evidence demonstrates that variabilities in responses to ART depend in part on genetic variants for certain drugs of abuse and its therapies. For instance, a NR1H3 gene variant affected methadone clearance only in those taking efavirenz. Two other genetic variants in the ABCB1 and CYP2B6 genes decreased methadone clearance. More research, though, is necessary to better understand the role of pharmacogenomics in people with HIV (PLWH) with substance use disorders (SUD). *NIDA is interested in receiving research proposals focusing on studying **pharmacogenomics** in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse.* This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2026.

## Funding Opportunity Announcements (FOA)

### 1. Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-084](#)

**Type:** R01

**Application Due Date:** May 15, 2023 through to January 13, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC: National Institute of Allergy and Infectious Diseases ([NIAID](#)) & National Institute on Aging ([NIA](#)) Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period of 6 or 7 years.

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105